Market Cap 472.51M
Revenue (ttm) 64.38M
Net Income (ttm) -56.42M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -87.64%
Debt to Equity Ratio 0.00
Volume 215,100
Avg Vol 250,770
Day's Range N/A - N/A
Shares Out 50.00M
Stochastic %K 100%
Beta 0.14
Analysts Sell
Price Target $13.80

Latest News on TBPH

Theravance Biopharma, Inc. (TBPH) Q3 2024 Earnings Call Transcript

Nov 12, 2024, 10:46 PM EST - 5 months ago

Theravance Biopharma, Inc. (TBPH) Q3 2024 Earnings Call Transcript


Theravance: Positive Findings Boost Ampreloxetine Development

Sep 9, 2023, 11:49 AM EDT - 1 year ago

Theravance: Positive Findings Boost Ampreloxetine Development